Highlights•Odanacatib is a new antiresorptive therapy with documented anti-fracture
efficacy.•Romosozumab is a new bone anabolic treatment that also inhibits resorption.• …

Current osteoporosis medications reduce fractures significantly but have rare and serious
adverse effects (osteonecrosis of the jaw, atypical femoral fractures) that may limit their …

Introduction: Osteoporosis is a common skeletal disease with serious consequences due to
osteoporotic fractures and high costs to society for post-fracture care. Most patients at high …

Antiresorptive agents are generally recommended as first-line treatment for osteoporosis in
postmenopausal women. These drugs suppress bone resorption but do not rebuild bone …

Introduction: Osteoporotic fracture is a cause of pain, loss of autonomy and excess mortality.
Current drugs however, do not allow for a satisfactory non vertebral fracture risk reduction …

There is a need for the development of new drugs to prevent osteoporosis-related fractures.
Fractures are projected to increase and the present drugs have modest efficacy, significant …

Osteoporosis and fragility fractures are relevant health issues because of their impact in
terms of morbidity, mortality, and socioeconomic burden. Despite this alarming scenario …

For the prevention of fractures, antiresorptive drugs (bisphosphonates and denosumab) that
decrease high bone resorption and, secondarily, also bone formation, are the mainstream of …

In patients with osteoporosis and severely reduced bone mass and/or recurring fractures,
antiresorptive therapy may not be the optimal first-line treatment. Two recent clinical trials …

Osteoporosis is a global public health concern with serious personal consequences and
high societal costs due to fractures (1). Medications are available that have been proven to …